PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressureenabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD-101 +/- checkpoint inhibition in metastatic uveal melanoma
… Enhanced delivery of anti PD-1 antibody to liver tumors in oncopig using pressure enabled drug delivery (PEDD) versus systemic delivery
… Pancreatic Venous Anatomy for Trans-Portal Treatment of Pancreatic Cancers using Pressure Enabled Drug Delivery (PEDD)
… The effects of a pressure-enabled drug delivery microcatheter on radiotracer distribution compared to a standard microcatheter in radioembolization, an interim analysis
… Hepatic Arterial Infusion of the Class C TLR9 Agonist SD-101 in Pressure Enabled Regional Immuno-Oncology (PERIO) Phase 1 Trials for Liver Tumors with authors.
… Pancreatic Retrograde Venous Infusion (PRVI) Significantly Enhances Delivery of NearIR Labelled SD-101 TLR9 Agonist to Targeted Regions of the Porcine Pancreas.
… Pressure-enabled intravascular delivery of SD-101 into the liver with systemic or subcutaneous checkpoint inhibitor for control of liver metastases in a murine model
… Pressure-Enabled Drug Delivery (PEDDTM) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model
… Enhanced Delivery of a TLR9 Type C Agonist SD-101 to Liver Tumors in the Oncopig using Pressure Enabled Drug Delivery (PEDD) Versus a Standard Endhole Catheter
… Improved delivery of a TLR-9 agonist to liver tissue by intravascular pressure enabled drug delivery (PEDD) compared with direct needle injection
…